未登录

胡伟伟 (Weiwei Hu)

china pharmaceutical university

H指数:16

被引数:725

个人简介

"胡伟伟，工学博士，讲师。2018年6月毕业于东南大学。任职于淮阴工学院化学工程学院，主要从事抗肿瘤药物的筛选、生物活性分子的作用靶点发现及结构改造等研究，在国外知名期刊发表SCI论文数篇…"

教育背景

2018.06
东南大学工学博士

工作经历

暂无内容

荣誉奖项

暂无内容

Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models

基于结构的首次发现靶向Talin2-β-整合素相互作用且在乳腺癌模型中具有强效体内抗肿瘤活性的抑制剂

Journal of Medicinal Chemistry

IF6.8

2026-04-220

PRE

Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma

鉴定一种靶向PLAGL2 DNA结合域的小分子可抑制细胞外基质形成并增强仑伐替尼在肝细胞癌中的敏感性

Acta Pharmaceutica Sinica B

IF14.6

2025-12-150

OAAI

PLAGL2 promotes HCC progression by recruiting tumour-associated macrophages via CCL2/CCR2 signalling

PLAGL2通过CCL2/CCR2信号募集肿瘤相关巨噬细胞促进HCC进展

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2025-12-010

PRE

Association between Triglyceride-Glucose Index and Prognosis in Critically Ill Patients with Acute Coronary Syndrome: Evidence from the MIMIC Database

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

IF3.2

2025-01-010

OAAI

Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA

发现基于Olaparib和Rigosertib的双靶向分子治疗具有野生型BRCA的三阴性乳腺癌

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2024-11-010

PRE

Stress-induced epinephrine promotes hepatocellular carcinoma progression via the USP10-PLAGL2 signaling loop

应激诱导肾上腺素通过USP10-PLAGL2信号环路促进肝癌进展

EXPERIMENTAL AND MOLECULAR MEDICINE

IF12.9

2024-05-011

OAAI

Gastrointestinal Fermentable Polysaccharide Is Beneficial in Alleviating Loperamide-Induced Constipation in Mice

IF5

2023-10-132

OAAI

The association between erector spinae muscle content and chronic heart failure and its severity

ESC HEART FAILURE

IF3.7

2023-07-310

OA

Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-03-2218

PRE

Differentiation therapy: Unlocking phenotypic plasticity of hepatocellular carcinoma

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IF5.6

2022-12-0114

PRE

Effect of chronic stress on tumorigenesis and development

CELLULAR AND MOLECULAR LIFE SCIENCES

IF6.2

2022-08-166

PRE

Characterization of a Type VI Secretion System vgrG2 Gene in the Pathogenicity of Burkholderia thailandensis BPM

FRONTIERS IN MICROBIOLOGY

IF4.5

2022-01-054

OAAI

2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop

PHARMACOLOGICAL RESEARCH

IF10.5

2021-07-0112

PREAI

PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity

IF15.8

2021-02-0662

PREAI

Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action

JOURNAL OF INORGANIC BIOCHEMISTRY

IF3.2

2018-09-0114

PREAI

Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria

JOURNAL OF INORGANIC BIOCHEMISTRY

IF3.2

2018-03-0134

PREAI

Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2017-12-0125

PREAI

Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance

JOURNAL OF INORGANIC BIOCHEMISTRY

IF3.2

2017-10-0162

PREAI

A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China

BIOSCIENCE REPORTS

IF4.7

2017-07-2712

OAAI

A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response

IF10.1

2017-01-0142

PREAI

研究方向

小分了抗肿瘤药物的设计与合成及作用机制研究生物活性小分子的作用靶点发现及结构修饰研究Hu, Weiwei, Zhao, JianHua, WuyangGou, Shaohua铂(IV)配合物逆转乳腺癌他莫昔芬耐药Hu, WeiweiFang, Lei抗癌前药靶向递送1Xu, Zichen1Hu, WeiweiWang, Zhimei铂(IV)前药多靶点抗癌作用机制Lyu, ChaojieGao, ChangzhongWu, KailiChen, LihuiZhu, Xixi锂离子电池Liu, Fengfan铂配合物合成生物活性评价

H 指数:5论文数:9被引数:152

H 指数:16论文数:67被引数:1,137

H 指数:32论文数:164被引数:2,672

H 指数:43论文数:402被引数:7,092

H 指数:50论文数:165被引数:7,964

H 指数:11论文数:26被引数:439

H 指数:0论文数:82被引数:0

H 指数:23论文数:122被引数:2,111

H 指数:47论文数:350被引数:8,130

H 指数:43论文数:352被引数:8,032